A. Reza Saadat
A. Reza Saadat
Send Message
A. Reza Saadat
Stop FollowingA. Reza Saadat
View as an RSS Feed
- Celgene Becomes a Bargain Once Again
- Amylin, Lilly: Another Case of a Panic Driven Sell-Off
- My Model Biotech Picks: What's Hot and What's Not
- Biogen-Idec, Elan: Panic Selling Creates Interesting Opportunity
- AMAG's Iron Replacement Therapy: Great Potential, Problematic Trial
- Amylin Has Yet to Crack Tough Diabetes Market
- Biotech Fundamentals Still Look Strong
- Vertex's Telaprevir May Become a Multi-Billion Dollar Drug
- Safety Data on Arena's Weight Loss Drug Could Pave Way for Good Partnership
- 2007 Biotech Performance Review
- Pharma, Biotech Present Great Investment Opportunities in 2008
- Biogen-Idec Looks Good Once Again
- Onyx's Cancer Drug: Potential Blockbuster - But With Competition
- Retail Investors Should Grasp Opportunity In Vertex Pharmaceuticals
- A Buyout Is No Certainty For Biogen-Idec
- Genzyme Breaks Out On Good News
- Pharmasset's Hepatitis C Drug Has A Promising Future
- Biotech Product Developments Should Make 2008 More Eventful Than 2007
- Altus Pharmaceuticals Makes Clinical And Financial Progress
- Vertex Pharmaceutical's Hepatitis Drug Proves Effective, But Path To Market Unclear
